ClinicalTrials.Veeva

Menu

Evolution and Treatments of Chronic Inflammatory Systemic Diseases (MISTIC)

C

Centre Hospitalier Universitaire de Besancon

Status

Enrolling

Conditions

Psoriasis
Spondyloarthritis
Psoriatic Arthritis
Ulcerative Colitis
Inflammatory Bowel Diseases
Verneuil's Disease
Crohn Disease
Arthritis, Rheumatoid

Study type

Observational

Funder types

Other

Identifiers

NCT04191395
P/2019/433

Details and patient eligibility

About

Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points. The pathologies concerned are inflammatory bowel diseases (IBD - Crohn's disease [MC] and ulcerative colitis [RCH]), chronic inflammatory skin diseases (psoriasis or Verneuil's disease) and chronic inflammatory rheumatic diseases (rheumatoid arthritis [RA] and spondyloarthritis [SpA] including psoriatic arthritis [PsA]). Presenting one of these diseases is associated with a higher risk of having a second inflammatory pathology, whether the latter is ophthalmological, dermatological, rheumatological or gastroenterological. An association of extra-articular manifestations is observed in 10 to 30% of patients with SpA, and an association of extra-intestinal manifestations is observed in approximately 30% of patients with IBD. No common database for chronic systemic inflammatory diseases currently exists in France.

Enrollment

3,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology department of Besançon University Hospital
  • Subject meeting the clinical, morphological and histological diagnostic criteria for MC, UC or indeterminate colitis or
  • Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the rheumatology department of the University Hospital of Besançon Subject meeting the ACR 2010 classification criteria of RA or modified New York criteria of Ankylosing spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA or
  • Patients treated for chronic inflammatory skin disease (Psoriasis, Verneuil's disease) in the dermatology department of the University Hospital of Besançon

Exclusion criteria

  • Opposition of the patient
  • Patients in emergency situation, persons deprived of their liberty, protected minors or adults.

Trial design

3,000 participants in 3 patient groups

Inflammatory bowel disease
Chronic inflammatory rheumatic disease
Chronic inflammatory skin diseases

Trial contacts and locations

1

Loading...

Central trial contact

Charline Vauchy, PhD; Stéphanie François

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems